Halozyme Therapeutics (HALO) FCF Margin (2010 - 2026)
Halozyme Therapeutics (HALO) posted quarterly FCF Margin of 46.81% for Q1 2026, down 1106.0% year-over-year from 4.65% in Q1 2025, and down 2.82% quarter-over-quarter from 48.17% in Q4 2025.
Halozyme Therapeutics (HALO) FCF Margin (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported FCF Margin for 17 consecutive years, with 46.81% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin fell 1106.0% year-over-year to 46.81%; the TTM figure through Mar 2026 stood at 44.26% (down 242.0% YoY), while the FY2025 annual figure was 46.15%, down 100.0% from the prior year.
- FCF Margin eased to 46.81% in Q1 2026 per HALO's latest filing, from 48.17% in the prior quarter.
- Across five years, FCF Margin topped out at 64.27% in Q1 2024 and bottomed at 25.43% in Q2 2024.
- Historically, FCF Margin has averaged 44.0% across 5 years, with a median of 44.14% in 2022.
- Annual changes were most pronounced in 2022 — FCF Margin plunged 7183 bps — and 2023, when it surged 2851 bps.
- Halozyme Therapeutics' FCF Margin stood at 44.14% in 2022, then fell by 14 bps to 38.08% in 2023, then soared by 64 bps to 62.36% in 2024, then decreased by 23 bps to 48.17% in 2025, then fell by 3 bps to 46.81% in 2026.
- Business Quant data shows HALO's FCF Margin at 46.81% in Q1 2026, 48.17% in Q4 2025, and 49.56% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 49.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 49.21% |
| Mar 31, 2026 | 46.81% |
| Dec 31, 2025 | 48.17% |
| Sep 30, 2025 | 49.56% |
| Jun 30, 2025 | 30.13% |
| Mar 31, 2025 | 57.87% |
| Dec 31, 2024 | 62.36% |
| Sep 30, 2024 | 37.31% |
| Jun 30, 2024 | 25.43% |
| Mar 31, 2024 | 64.27% |
| Dec 31, 2023 | 38.08% |
| Sep 30, 2023 | 61.35% |
| Jun 30, 2023 | 30.12% |
| Mar 31, 2023 | 53.39% |
| Dec 31, 2022 | 44.14% |
| Sep 30, 2022 | 32.84% |
| Jun 30, 2022 | 25.65% |
| Mar 31, 2022 | 40.49% |
| Dec 31, 2021 | 82.10% |
| Sep 30, 2021 | 104.67% |